Yabao and Sciecure Pharma to develop, manufacture and commercialise generics for US and China
No financial terms are released
Chinese company Yabao Pharmaceutical is to partner Sciecure Pharma, a privately owned speciality pharmaceutical company engaged in the research and development of drug delivery technologies, to develop, manufacture and commercialise high technological barrier controlled release generic medicines for the US and China markets.
Under the terms of the agreement, Yabao will exclusively own rights to commercialise certain Sciecure Pharma-developed products in China and manufacture for both the US and China markets, while Monmouth Junction, NJ, US-based Sciecure will retain rights to commercialise in the US and all other markets.
Financial terms were not disclosed.
